The folks at the FDA have scheduled a meeting to review the safety of Trasylol, which has been under government scrutiny for more than a year.
Trasylol was approved for U.S. marketing in 1993 to reduce the need for blood transfusions in bypass surgeries.
On September 12, 2007 the FDA will review documents that may show Trasylol can cause kidney damage, heart failure and even death.
More information here.
